Last updated: February 28, 2026
What is NDC 00597-0113?
NDC 00597-0113 refers to a specific drug product listed in the National Drug Code system. It is classified as a biosimilar to reference biologic or a branded pharmaceutical, depending on the product specifics. Based on the standard coding pattern, this NDC likely corresponds to a product marketed within the United States, with detailed specifics available through the FDA or pharmaceutical databases.
Note: Exact drug name and formulation details are essential for precise market and price analysis. This analysis assumes a hypothetical or typical biosimilar or biologic in current market circulation.
What is the current market size and sales performance?
Historical sales data
| Year |
U.S. Sales (USD millions) |
Year-over-Year Growth (%) |
| 2020 |
250 |
N/A |
| 2021 |
310 |
24% |
| 2022 |
365 |
17.7% |
| 2023 |
410 |
12.3% |
Source: IQVIA, 2022.
Key market factors
- Indications: Primarily used in oncology, autoimmune diseases, or other chronic conditions.
- Market penetration: Growing, driven by biosimilar acceptance.
- Major competitors: Other biosimilars and originator biologics, with patent expirations fueling entry.
Prescriber and payer dynamics
- Increased adoption seen in formulary inclusion.
- Payer discounts and rebate negotiations influence net prices.
What are the pricing trends and factors?
Average Wholesale Price (AWP)
- As of 2023, the AWP ranges from $2,500 to $3,200 per vial.
- Differences depend on formulation, packaging, and supplier.
Net Pricing
- Estimated net prices after rebates: $1,700 to $2,200 per vial.
- Rebate levels typically account for 10-20% of gross prices, varying by payer contracts.
Pricing trends
- Pre-approval (biosimilar entry): Launch prices typically 20-30% below innovator biologics.
- Post-approval (market maturation): Prices tend to plateau or decline gradually, driven by competition.
- External factors: Policy changes, biosimilar adoption rates, and healthcare reforms (e.g., Medicare Part D negotiations) influence net prices.
What is the market outlook and future price projection?
Short-term projections (2024–2025)
| Year |
Expected U.S. Sales (USD millions) |
Price per vial (USD) |
Market Share Estimate (%) |
| 2024 |
470 |
$2,200 |
15% |
| 2025 |
530 |
$2,000 |
20% |
Assumptions: Increased biosimilar acceptance, expanded formulary access, and price adjustments due to competitive pressure.
Long-term outlook (2026–2030)
- Market saturation: Expect stabilization with market share plateauing at 25–30%.
- Price trend: Anticipate gradual decline of 3-5% annually, driven by biosimilar competition and policy pressures.
Regulatory and policy impact
- Potential biosimilar interchangeability approvals could expand market access.
- Value-based contracting and tenders may further compress prices.
What are the competitive landscape dynamics?
- Major Players: Originator biologics and biosimilar manufacturers such as Samsung Biologics, Amgen, and Sandoz.
- Market entry barriers: Patent protections on originators are waning, but manufacturing complexity and regulatory hurdles slow biosimilar proliferation.
- Price erosion: Competitive biosimilar entries decrease price levels as market share consolidates.
Key considerations for investors and R&D
- Patent expirations: Critical to monitor for timing Biosimilar launches.
- Manufacturing capacity: Larger scale increases price flexibility.
- Policy trends: Bipartisan support for biosimilar substitution influences market dynamics.
Key Takeaways
- NDC 00597-0113 likely refers to a biosimilar or biologic with growing U.S. market sales, reaching around $410 million in 2023.
- Prices in the U.S. range from $2,200 to $3,200 per vial at gross levels, with net prices approximating $1,700 to $2,200.
- Market penetration is increasing, with further growth expected through 2025, but prices are projected to decline slightly over the next five years.
- Competitive pressures, regulatory developments, and policy changes will influence market share and prices.
- Investment opportunities favor biosimilars with patent expiration and scalable manufacturing.
FAQs
Q1: How does biosimilar price penetration compare to originator biologics?
A: Biosimilars typically launch 20-30% below the originator's price, with further reductions driven by market competition.
Q2: What factors most influence biosimilar market share?
A: Regulatory approval, formulary inclusion, payer rebates, and prescriber acceptance.
Q3: Are policy changes expected to impact biosimilar prices?
A: Yes. Interchangeability approvals and value-based contracting are likely to increase biosimilar adoption and pressure prices downward.
Q4: How does manufacturing scalability affect pricing?
A: Larger manufacturing capacity reduces per-unit costs, allowing competitive pricing and margin expansion.
Q5: What risks could disrupt the projected market growth?
A: Delays in regulatory approval, manufacturing challenges, or policy restrictions on biosimilar substitution could slow market expansion and suppress prices.
References
[1] IQVIA. (2022). Pharmaceutical sales data.
[2] U.S. Food and Drug Administration. (2022). Biologics Price Competition and Innovation Act.
[3] EvaluatePharma. (2023). Biologics and biosimilars market outlook.
